KM Research Hub
← 返回论文库
无 KM 图 入排:符合 图源:可得 入排置信度 0.98

Health-related quality of life with daratumumab, bortezomib, melphalan, and prednisone versus bortezomib, melphalan, and prednisone alone in transplant-ineligible patients with newly diagnosed multiple myeloma: analysis of the phase 3 OCTANS study.

Weijun Fu, Soo-Mee Bang, Honghui Huang, Kihyun Kim, Wei Li, Gang An, Je-Jung Lee, Zhen Cai, Jie Jin, Yafei Wang, Chor Sang Chim, Robin Carson, Rui Liu, Man Zhao, Xi Chen, Canchan Cui, Jian Hou, Jianxiang Wang

Ann Hematol 104(5) 2765-2776

PMID40407887
PMCIDPMC12141397
DOI10.1007/s00277-025-06303-3
发表日期2025-05-23
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:历史记录已完成可用 Figure 视觉审查,未识别 KM 曲线。
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 5 张 PMC Figure,均未识别为 KM 图:Fig. 1:生活质量量表图;Fig. 2:生活质量量表图;Fig. 3:生活质量量表图;Fig. 4:生活质量量表图;Fig. 5:生活质量量表图。
摘要

摘要

In the phase 3 OCTANS study, daratumumab plus bortezomib/melphalan/prednisone (D-VMP) significantly improved response rates and progression-free survival versus VMP alone in transplant-ineligible Asian patients with newly diagnosed multiple myeloma (NDMM). Understanding the impact of treatment on patient-reported outcomes (PROs) is of increasing interest. Here, we report on the impact of D-VMP and VMP on PROs in OCTANS. PROs were a secondary endpoint and were assessed using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30-item (EORTC QLQ-C30) and the EuroQol 5-dimensional descriptive system (EQ-5D-5L) questionnaire, administered at screening, every 3 months (Year 1), every 6 months thereafter (until disease progression), and 8 and 16 weeks post disease progression. Treatment effects were estimated using a mixed-effects model with repeated measures. Overall, 220 patients were randomized (D-VMP, n = 146; VMP, n = 74). Compliance rates were 100% at baseline in both treatment groups and remained relatively high by Month 12 (D-VMP, 82.6%; VMP, 67.4%). Comparable improvements from baseline were generally observed between treatment groups across most PRO scores. Significant improvements were observed with D-VMP versus VMP in Global Health Status (GHS) score at 9 months (p = 0.0443) and in social functioning and nausea and vomiting symptom scores at 12 months (p = 0.0042 and p = 0.0012, respectively). In summary, transplant-ineligible Asian patients with NDMM demonstrated improvements in PROs following treatment with D-VMP and VMP; however, greater improvements were observed in GHS, social functioning, and nausea and vomiting symptoms with D-VMP.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(5,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Fig. 1Change from baseline in EORTC QLQ-C30 GHS score. EORTC QLQ-C30, European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30-item; GHS, Global Health Status; LS, least squares; CI, confidence interval; D-VMP, daratumumab plus bortezomib/melphalan/prednisone; VMP, bortezomib/melphalan/prednisone; ISS, International Staging System. LS means are derived based on the mixed-effects model with repeated measures, in which the dependent variable is change from baseline in score, and independent variables are baseline, visit, treatment, visit by treatment interaction, and randomization stratification factors—ISS staging (I, II, III) and age (< 75 years vs. ≥ 75 years)—as fixed effects and individual patient as random effect
非 KM Figure
Fig. 2Change from baseline in EORTC QLQ-C30 functional domain scores for a ) physical functioning, b ) role functioning, c ) emotional functioning, d ) cognitive functioning, and e ) social functioning. EORTC QLQ-C30, European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30-item; LS, least squares; CI, confidence interval; D-VMP, daratumumab plus bortezomib/melphalan/prednisone; VMP, bortezomib/melphalan/prednisone; ISS, International Staging System. LS means are derived based on the mixed-effects model with repeated measures, in which the dependent variable is change from baseline in score, and independent variables are baseline, visit, treatment, visit by treatment interaction, and randomization stratification factors—ISS staging (I, II, III) and age (< 75 years vs. ≥ 75 years)—as fixed effects and individual patient as random effect
非 KM Figure
Fig. 3Change from baseline in EORTC QLQ-C30 symptom domain scores for a ) pain, b ) fatigue, and c ) nausea and vomiting. EORTC QLQ-C30, European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30-item; LS, least squares; CI, confidence interval; D-VMP, daratumumab plus bortezomib/melphalan/prednisone; VMP, bortezomib/melphalan/prednisone; ISS, International Staging System. LS means are derived based on the mixed-effects model with repeated measures, in which the dependent variable is change from baseline in score, and independent variables are baseline, visit, treatment, visit by treatment interaction, and randomization stratification factors—ISS staging (I, II, III) and age (< 75 years vs. ≥ 75 years)—as fixed effects and individual patient as random effect
非 KM Figure
Fig. 4Percentage of patients reporting clinically meaningful improvement in EORTC QLQ-C30 GHS, functional, and symptom scales at 24 months. EORTC QLQ-C30, European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30-item; GHS, Global Health Status; D-VMP, daratumumab plus bortezomib/melphalan/prednisone; VMP, bortezomib/melphalan/prednisone. Clinically meaningful improvement was defined as ≥ 10-point improvement from the baseline score. No. of patients is the number of patients with a minimally important difference in each treatment group
非 KM Figure
Fig. 5EQ-5D-5L results for a ) change from baseline in VAS score, b ) change from baseline in utility score, and c ) the percentage of patients reporting clinically meaningful improvement in VAS score over 24 months. EQ-5D-5L, EuroQol 5-dimensional descriptive system; VAS, visual analog scale; LS, least squares; CI, confidence interval; D-VMP, daratumumab plus bortezomib/melphalan/prednisone; VMP, bortezomib/melphalan/prednisone; ISS, International Staging System. LS means are derived based on the mixed-effects model with repeated measures, in which the dependent variable is change from baseline in score, and independent variables are baseline, visit, treatment, visit by treatment interaction, and randomization stratification factors—ISS staging (I, II, III) and age (< 75 years vs. ≥ 75 years)—as fixed effects and individual patient as random effect. Clinically meaningful improvement was defined as ≥ 7-point improvement from the baseline score. No. of patients is the number of patients with VAS results in each treatment group at each time point
非 KM Figure